glucose lowering for cardiovascular prevention

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

diabetes type 2

aleglitazar
ALEPREVENT     aleglitazarplaceboLow risk of bias -
ALECARDIO, 2014      NCTaleglitazarplaceboLow risk of bias negative
alogliptin
EXAMINE, 2013      NCTalogliptinplaceboLow risk of bias negative
canagliflozin
CANVAS, 2017            NCTcanagliflozinplaceboLow risk of bias conclusive
empagliflozin
EMPA-REG OUTCOME, 2015      NCTempagliflozinplaceboLow risk of bias conclusive
exenatide
EXSCEL, 2017    NCTexenatideplaceboLow risk of bias conclusive
glargine
ORIGINE, 2012      NCTinsulin glarginecontrolnegative
linagliptin
CAROLINA, 2012      NCTlinagliptinglimepirideLow risk of bias suggesting
liraglutide
LEADER, 2016      NCTliraglutideplaceboLow risk of bias conclusive
lixisenatide
ELIXA          NCTlixisenatideplaceboLow risk of bias negative
pioglitazone
PROACTIVE      NCTpioglitazoneplacebo -
IRIS, 2016      NCTpioglitazoneplacebo -
saxagliptin
SAVOR TIMI, 2013      NCTsaxagliptinplaceboLow risk of bias negative
semaglutide
SUSTAIN 6, 2016      NCTsemaglutideplaceboLow risk of bias conclusive
sitagliptin
TECOS, 2015          NCTsitagliptinplaceboLow risk of bias negative